Cargando…

Correction: BAK and NOXA Are Critical Determinants of Mitochondrial Apoptosis Induced by Bortezomib in Mesothelioma

Detalles Bibliográficos
Autores principales:	Busacca, Sara, Chacko, Alex D., Klabatsa, Astero, Arthur, Kenneth, Sheaff, Michael, Barbone, Dario, Mutti, Luciano, Gunasekharan, Vignesh K., Gorski, Julia J., El-Tanani, Mohamed, Broaddus, V. Courtney, Gaudino, Giovanni, Fennell, Dean A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875287/ http://dx.doi.org/10.1371/annotation/90879c69-ebc5-40b2-9926-4a00e4f9e055

Ejemplares similares

BAK and NOXA Are Critical Determinants of Mitochondrial Apoptosis Induced by Bortezomib in Mesothelioma
por: Busacca, Sara, et al.
Publicado: (2013)

Vorinostat Eliminates Multicellular Resistance of Mesothelioma 3D Spheroids via Restoration of Noxa Expression
por: Barbone, Dario, et al.
Publicado: (2012)

Autophagy Correlates with the Therapeutic Responsiveness of Malignant Pleural Mesothelioma in 3D Models
por: Barbone, Dario, et al.
Publicado: (2015)

Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma
por: Leshchenko, Violetta V., et al.
Publicado: (2015)

Analysis of Gene Expression in 3D Spheroids Highlights a Survival Role for ASS1 in Mesothelioma
por: Barbone, Dario, et al.
Publicado: (2016)

BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms
por: Singh, Anita, et al.
Publicado: (2022)

Dynamical Systems Analysis of Mitochondrial BAK Activation Kinetics Predicts Resistance to BH3 Domains
por: Grills, Claire, et al.
Publicado: (2008)

The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance
por: Barbone, D, et al.
Publicado: (2011)

Autophagy initiation correlates with the autophagic flux in 3D models of mesothelioma and with patient outcome
por: Follo, Carlo, et al.
Publicado: (2016)

Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms
por: Nguyen, Tri, et al.
Publicado: (2018)

Current Advances in CAR T Cell Therapy for Malignant Mesothelioma
por: Klampatsa, Astero, et al.
Publicado: (2020)

Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial
por: Fennell, Dean A., et al.
Publicado: (2022)

Antitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum stress in vitro and activation of T cell response in vivo
por: Benvenuto, Monica, et al.
Publicado: (2023)

Characterization of bortezomib-adapted I-45 mesothelioma cells
por: Zhang, Lidong, et al.
Publicado: (2010)

Circumventing HSP90 inhibitors via apoptosis block
por: Fennell, Dean A., et al.
Publicado: (2015)

Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma
por: Porta, Camillo, et al.
Publicado: (2008)

Resistance to HSP90 inhibition involving loss of MCL1 addiction
por: Busacca, S, et al.
Publicado: (2016)

Precision Therapy for Mesothelioma: Feasibility and New Opportunities
por: Dulloo, Sean, et al.
Publicado: (2021)

MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib
por: Wirth, Matthias, et al.
Publicado: (2014)

Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA
por: Heine, Simon, et al.
Publicado: (2018)

BAK-up: the receptor kinase BAK-TO-LIFE 2 enhances immunity when BAK1 is lacking
por: Fallahzadeh-Mamaghami, Vahid, et al.
Publicado: (2023)

Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives
por: Gray, Steven G., et al.
Publicado: (2020)

Mesothelioma: Hippo pathway as a target, lessons from COMMAND
por: Fennell, Dean A., et al.
Publicado: (2019)

A Glimpse in the Future of Malignant Mesothelioma Treatment
por: Pezzicoli, Gaetano, et al.
Publicado: (2021)

Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis
por: Cerruti, Fulvia, et al.
Publicado: (2017)

Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment
por: Zhang, Min, et al.
Publicado: (2021)

Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors
por: Echeverry, N, et al.
Publicado: (2015)

Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)
por: Klampatsa, Astero, et al.
Publicado: (2017)

Identification of Overexpressed Genes in Malignant Pleural Mesothelioma
por: Morani, Federica, et al.
Publicado: (2021)

Playing FullBAK
por: Walensky, Loren D.
Publicado: (2013)

Cancer chemoresistance and BAK
por: Fox, Joanna L.
Publicado: (2015)

Robust autoactivation for apoptosis by BAK but not BAX highlights BAK as an important therapeutic target
por: Iyer, Sweta, et al.
Publicado: (2020)

Intratumor microbiota as a novel potential prognostic indicator in mesothelioma
por: Pentimalli, Francesca, et al.
Publicado: (2023)

Switching off malignant mesothelioma: exploiting the hypoxic microenvironment
por: Nabavi, Noushin, et al.
Publicado: (2016)

Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy
por: Harber, James, et al.
Publicado: (2021)

Author Correction: Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment
por: Zhang, Min, et al.
Publicado: (2021)

Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles' heel in mantle cell lymphoma
por: Dengler, M A, et al.
Publicado: (2014)

In vitro and in vivo characterization of highly purified Human Mesothelioma derived cells
por: Melotti, Alice, et al.
Publicado: (2010)

How asbestos and other fibers cause mesothelioma
por: Gaudino, Giovanni, et al.
Publicado: (2020)

NOXA as critical mediator for drug combinations in polychemotherapy
por: Ehrhardt, H, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_tfr8929pkqj2ud6v7ksijdatkk